Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
To read the full story
Related Article
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
- GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
- GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
December 13, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
ACADEMIA
- NCCH Launches Pilot for Online Screening of Clinical Trial Participants
March 6, 2025
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
- Moves Being Made to Resolve Japan’s Drug Lag in Sarcoma: Oncologist
February 25, 2025
- 1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?
February 25, 2025
- Oncologist Sees Need to Seek Middle Ground towards CGP Testing for 1st Line Therapy
February 17, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…